Tables
- Table 1– Main study outcomes
All subjects Group A Group B Group C p-value Subjects n 55 5 19 Females 40/77 (52) 29 3 8 >0.1 Age at diagnosis with sarcoidosis yrs 44 (41–47) 42 (38–46) 52 (43–62) 49 (42–56) >0.1 Age at diagnosis with NHL yrs 52 (48–56) Age at diagnosis with HL yrs 45 (39–51) Interval between diseases months 96 (69–123) 36 (7–65) <0.05 NHL 48/76 (63) 32 5 11 >0.1 HL 28/76 (37) 20 0 8 >0.1 Stage 0 11/73 (15) 8 1 2 >0.1 Stage I 21/73 (29) 14 2 5 >0.1 Stage II 21/73 (29) 16 0 5 >0.1 Stage III 20/73 (27) 14 2 4 >0.1 Organs involved in sarcoidosis 3 (2.6–3.4) 2.4 (1–3.8) 2 (1.5–2.4) <0.05 After second disease onset Cough 3/40 4/16 0.09 Dyspnoea 4/40 6/16 <0.05 Elevated ACE 0/40 4/16 <0.05 Lung 0/40 9/16 <0.05 BHL 2/40 8/16 <0.05 Skin 3/40 4/16 0.09 Lymph nodes 20/40 0/16 <0.05 Spleen 13/40 0/16 <0.05 Data are presented as n/N (%), mean (95% CI) or n/N, unless otherwise stated. NHL: non-Hodgkin Lymphomal; HL: Hodgkin Lymphoma; ACE: angiotensin-converting enzyme; BHL: bilateral hilar lymphadenopathy.
Vol 36 Issue 5
Table of Contents
The relationship between sarcoidosis and lymphoma
